Clinical and Experimental Vaccine Research

  • 제11권3호
  • /
  • Pages.298-301
  • /
  • 2022
  • /
  • 2287-3651(pISSN)
  • /
  • 2287-366X(eISSN)
대한백신학회 (The Korean Vaccine Society)
권호 표지
DOI QR코드

DOI QR Code

Livedo reticularis following administration of ChAdOx1 nCoV-19 vaccine (AZD1222): a report of two cases

  • Joong Ho Kim (Department of Dermatology, Inje University Sanggye Paik Hospital) ;
  • Ji An Uh (Department of Dermatology, Inje University Sanggye Paik Hospital) ;
  • Ho Sung Kim (Department of Dermatology, Inje University Sanggye Paik Hospital) ;
  • Soo Kyung Lee (Department of Dermatology, Inje University Sanggye Paik Hospital) ;
  • Myoung Shin Kim (Department of Dermatology, Inje University Sanggye Paik Hospital) ;
  • Un Ha Lee (Department of Dermatology, Inje University Sanggye Paik Hospital)
  • 투고 : 2022.09.30
  • 심사 : 2022.10.25
  • 발행 : 2022.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The cutaneous appearance of transient or persistent livedo reticularis is characterized by violaceous, mottled, ring-shaped interconnecting lesions that form a reticular or net-like pattern. It can occur physiologically in response to cold exposure, such as in cutis marmorata, but can also be induced by pathological conditions such as vascular obliterans or venodilation. We report two cases of livedo reticularis that occurred on the lower limbs of two patients post ChAdOx1 nCoV-19 vaccination. As the patients had no other likely causes of livedo reticularis, the reticular skin lesions were suspected to occur in association with the ChAdOx1 nCoV-19 vaccination. Livedo reticularis is an uncommon adverse reaction, with few cases being reported post ChAdOx1 nCoV-19 vaccination.

키워드

참고문헌

  1. Gibbs MB, English JC 3rd, Zirwas MJ. Livedo reticularis: an update. J Am Acad Dermatol 2005;52:1009-19.
  2. Sajjan VV, Lunge S, Swamy MB, Pandit AM. Livedo reticularis: a review of the literature. Indian Dermatol Online J 2015;6:315-21.
  3. Freeman EE, McMahon DE, Lipoff JB, et al. The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries. J Am Acad Dermatol 2020;83:1118-29.
  4. Berezne A, Bougon D, Blanc-Jouvan F, et al. Deterioration of vaccine-induced immune thrombotic thrombocytopenia treated by heparin and platelet transfusion: Insight from functional cytometry and serotonin release assay. Res Pract Thromb Haemost 2021;5:e12572.
  5. Cameli N, Silvestri M, Mariano M, Nistico SP, Cristaudo A. Pernio-like skin lesions after the second dose of Pfizer-BioNTech COVID-19 vaccine. J Eur Acad Dermatol Venereol 2021;35:e725-7.
  6. In SI, Han JH, Kang HY, Lee ES, Kim YC. The histopathological characteristics of livedo reticularis. J Cutan Pathol 2009;36:1275-8.
  7. Greinacher A, Selleng K, Palankar R, et al. Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood 2021;138:2256-68.
  8. Ramessur R, Saffar N, Czako B, Agarwal A, Batta K. Cutaneous thrombosis associated with skin necrosis following Oxford-AstraZeneca COVID-19 vaccination. Clin Exp Dermatol 2021;46:1610-2.
  9. Cavalli G, Colafrancesco S, De Luca G, et al. Cutaneous vasculitis following COVID-19 vaccination. Lancet Rheumatol 2021;3:e743-4.
  10. Karimi Galougahi K. Autonomic dysfunction post-inoculation with ChAdOx1 nCoV-19 vaccine. Eur Heart J Case Rep 2021;5:ytab472.
  11. Bradford WD, Cook CD, Vawter GF. Livedo reticularis: a form of allergic vasculitis: report of 3 cases. J Pediatr 1962;60:266-76.
  12. Mintz MA, Jariwala N, Fang V, Coromilas A, Rosenbach M. Livedo reticularis on bilateral knees after the third dose of messenger RNA-1273 SARS-CoV-2 vaccine. JAAD Int 2022;7:52-3.
  13. Annabi E, Dupin N, Sohier P, et al. Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature. J Eur Acad Dermatol Venereol 2021;35:e847-50.
  14. Dean SM. Livedo reticularis and related disorders. Curr Treat Options Cardiovasc Med 2011;13:179-91.
  15. Thareja S, Paghdal K, Lien MH, Fenske NA. Reticular erythematous mucinosis: a review. Int J Dermatol 2012;51:903-9.